DXCM

Based on DexCom, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

What does DexCom do?

DexCom designs and sells continuous glucose monitoring systems that allow people with diabetes to track their blood sugar levels in real time without routine finger-stick testing. The company markets its devices to physicians, endocrinologists, and diabetes educators, and also enables third-party health app developers to integrate its CGM data through an open API.

Does DXCM pay dividends?

DexCom does not pay a dividend. The company reinvests its capital into product development, commercial expansion, and strategic partnerships. Investors focused on income generation should factor this into their assessment of DXCM relative to dividend-paying healthcare peers.

When does DXCM report earnings?

DexCom reports financial results on a quarterly basis, in line with standard US-listed company practice. For exact reporting dates and the most recent results, check DexCom's official investor relations page.

Is DXCM a good stock to buy?

UQS Score rates DXCM as Good overall. The Quality, Growth, and Risk pillars all register positively, while Moat and Valuation are Neutral. Whether DXCM fits your portfolio depends on your risk tolerance and investment horizon. The full pillar breakdown is available to UQS Pro members.

Is DXCM overvalued?

DXCM's Valuation pillar is rated Neutral, suggesting the stock is neither clearly cheap nor obviously expensive relative to its fundamentals. The market appears to have priced in a significant portion of the company's growth expectations. Pro members can view the complete valuation metrics behind this rating.

How does DXCM compare to its competitors?

DexCom occupies a specialized niche in continuous glucose monitoring, while peers like Philips and STERIS operate across broader healthcare device and services segments. DexCom's focused product portfolio in diabetes management differentiates it from more diversified medical device companies. See the competitor comparison section above for more context.

What is DXCM's market cap bracket?

DexCom is classified as a large-cap company, placing it among the more established and widely followed names in the medical device sector. Large-cap status generally reflects meaningful revenue scale and institutional investor coverage.

Who founded DexCom?

DexCom was founded by John F. Burd and others, with the company incorporated in 1999 and headquartered in San Diego, California. Full founding history is publicly available through DexCom's corporate and investor relations materials.

Is DXCM a long-term quality indicator?

From a quality-scoring perspective, DXCM's Good ratings across Quality, Growth, and Risk pillars suggest a business with durable characteristics worth monitoring over a longer horizon. The Neutral Moat rating is a consideration — sustainable competitive advantage is a key factor in long-term quality assessments. Pro members can explore the full breakdown.

What is the main competitive advantage of DexCom?

DexCom's primary competitive advantage lies in its specialized focus on CGM technology, its established relationships with diabetes care providers, and its ecosystem of third-party integrations through the Dexcom Real-Time API. However, the UQS Moat pillar rates this advantage as Neutral, reflecting ongoing competitive pressure in the CGM market.

What sector does DXCM belong to?

DexCom is classified in the Healthcare sector, specifically within the medical devices industry. It focuses on diabetes management technology, a segment experiencing growing demand as global diabetes prevalence rises and CGM adoption expands beyond Type 1 into the broader Type 2 patient population.

Is DXCM a growth stock or value stock?

Based on its UQS pillar profile, DXCM leans toward the growth side — the Growth pillar is rated Good, reflecting meaningful expansion potential. The Valuation pillar is Neutral, suggesting the stock is not priced as a deep-value opportunity. It may appeal more to growth-oriented investors than those seeking undervalued assets.

DexCom, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.

DexCom, Inc. faces growth headwinds with declining or stagnant revenue trends.

DexCom, Inc. has some risk factors including moderate leverage or solvency concerns.

DexCom, Inc. appears expensively valued relative to its fundamentals and growth prospects.

DexCom, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for DXCM.

The UQS (Unified Quality Score) for DexCom, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses DexCom, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether DexCom, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.